C-BE5ESana Biotechnology
engineered cells, gene repair, cell replacement
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BE5E
C-BE5EC-BE5Eengineered cells, gene repair, cell replacement
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Effective postoperative pain management is essential after thoracic surgery. Insufficient pain control may impair breathing and coughing, increasing the risk of pulmonary complications such as collapsed lungs (atelectasis) or pneumonia. Although minimally invasive lung surgery (video-assisted thoracoscopic surgery, VATS) is less painful than open surgery, people can still have significant pain after the operation. The goal of this randomized comparative study is to compare two commonly used regional anesthesia techniques for pain control after VATS in adults. Researchers will compare an ultrasound-guided erector spinae plane block (ESPB), performed by anesthesiologists, to a thoracoscopically-guided intercostal nerve block (ICNB), performed by surgeons. Participants will: * Undergo elective VATS lung resection surgery * Receive either ESPB or ICNB, according to random assignment * Have the received amount of analgesics recorded during the first 24 hours * Have their pain levels assessed at predefined time points after surgery The main questions this study aims to answer are: * Does ESPB result in similar analgesic consumption in the first 24 hours after surgery? * Does ESPB provide similar postoperative pain relief compared to ICNB? * Is the time needed to perform ESPB similar to ICNB?
This is study designed to confirm the effectiveness of the Sana Device in patients with pain due to fibromyalgia on quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR). It is a two arm study in which subjects will be randomly assigned to either active device group or sham-controlled group.
What happens when a biotech company promises breakthrough research but ends up running on empty? Sana Biotechnology assured investors it had enough cash to fund its cancer drug trials for years. But by late 2024, it halted research on all major projects, revealing a severe cash crunch. Furious investors bailed, sending Sana’s stock down ten percent. Want to know how it all unraveled? 🎥 Watch the full breakdown—https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?wire=40 Disclaimer: This post is for educational purposes only and does not constitute financial advice. #InvestorAlert #ClassAction #SANA #SanaBiotechnology
The Transversus Abdominis Plane Block (TAP) has become one of the most established and frequently performed trunk wall blocks for perioperative analgesia in abdominal surgical procedures. The TAP-Block can be performed by both surgeons and anaesthetists. The goal of this prospective, randomized study is to compare an anesthesiological, ultrasound-guided "Transversus Abdominis Plane (TAP) Block" with a laparoscopic, landmark-based "Transversus Abdominis Plane (TAP) Block" The main questions it aims to answer are: Primary Hypothesis: There are no differences in postoperative pain perception and analgesic requirements between the anaesthesiological ultrasound-guided and the surgical laparoscopic landmark-based TAP block Secondary Hypothesis: There are no significant differences in the duration of the procedure between the anaesthesiological, ultrasound-guided and the surgical laparoscopic landmark-based TAP block.
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
The purpose of this study is to assess the effectiveness of the Sana Device when added to Treatment as Usual in participants with a diagnosis of post-traumatic stress disorder (PTSD)
When opposed to GA,SA is recommended during c section. Shivering is more prevalent and inconvenient complication of spinal anaesthesia, with 40 to 70% incidence rate. Tramadol has been proven to be beneficial in preventing post spinal shivering. Dexmedetomidine is a sedative, analgesic, anxiolytic, sympatholytic and opioid-sparing alpha adrenergic agonist. It has been shown to lower the threshold for shivering. The study aims to search for best drug for blunting shivering response.
Metastatic disease to the bone is a common cause of pain. External beam radiation therapy (EBRT) is the standard palliative treatment BUT pain improvement is observed in 60% to 80%. Combination of hyperthermia (HT) with radiation is strongly compelling. MR is providing accurate, tissue-independent thermometry for intra-procedural guidance of thermal therapy. In this project we aim to combine in an adjuvant setting mild hyperthermia to EBRT for sustained relief of pain in patients with symptomatic bone metastases.
This study is designed to compare two different surgical methods for repairing ventral abdominal wall hernias: sublay mesh repair and onlay mesh repair. Ventral hernias are common and occur when tissue pushes through a weak spot in the abdominal wall. Both sublay and onlay techniques involve placing a synthetic mesh to strengthen the abdominal wall, but the position of the mesh differs. This trial will evaluate postoperative outcomes, including surgical wound infections, seroma (fluid buildup), and hernia recurrence, over a six-month follow-up period. The findings are expected to help inform surgical decision-making, particularly in resource-limited hospitals.
Objective: The objective of this study was to evaluate the prevalence and impact of diabetes mellitus on the severity and mortality of COVID-19. Methods: Data of laboratory-confirmed hospitalized patients at the COVID-19 unit of Ibn El Jazzar University Hospital in Kairouan between September 2020 and August 2021 were analysed, in a cross-sectional study. The population was classified into two groups (COVID-19 patients with versus without diabetes). Primary outcomes were the overall length of hospital stay, the admission to the intensive care unit (ICU), and death.
The purpose of this research study is to evaluate the effectiveness of an experimental device called the Sana Pain Reliever Device (Sana Device) on treating pain due to fibromyalgia.
There is a lack of long-term data on the impact of bariatric surgery in type 1 diabetes (T1D). The aim of this study is to gain long-term outcome data on the effects of bariatric surgery in obese patients with T1D.
Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy
Detection of early esophageal cancer in surrounding normal tissue can be challenging even for experienced examiners. The early detection is essential to determine the following treatment. Early stages of esophageal cancers can be treated by endoscopic resection whereas advanced neoplasia might lead to an Operation of the esophagus. Diagnosis is made usually by biopsies of suspicious lesions or untargeted quadrant biopsies. The electrical properties in inflammatory tissue and cancer can be sensed by electrical bioimpedance technique. The aim of this study is to compare the impedance probe with the histological result and to investigate the feasibility of the new technique in detection of esophageal cancer.
The aim of this prospective randomized controlled trial is to compare the two procedures One-anastomosis gastric Bypass/Mini-gastric Bypass (OAGB/MGB) and Roux-en Y gastric bypass (RYGB) in relation to intraoperative and postoperative complications (classification of Clavien-Dindo), mortality, metabolic impact (remission of type 2 diabetes mellitus, hypertonus, gastro-esophageal reflux disease, sleep apnea, dyslipidemia, quality of life, operation time, postoperative excess weight loss, malnutrition and re-do/revisonal surgery.
To evaluate addiction remission and addiction transfer after bariatric surgery.
The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than BMI or waist circumference. EOSS is also important in predicting post - operative outcome and 30-day mortality after metabolic surgery. The aim of this study is to determine whether EOSS could be an indicator for procedure selection in obesity and metabolic surgery.
To evaluate the impact of obesity surgery on chronic inflammation.
The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than BMI or waist circumference. The aim of this study is to determine whether the EOSS is also important in predicting post - operative outcome and 30-day mortality after metabolic surgery.
Sleeve Gastrectomy is the most performed bariatric procedure worldwide. But a growing number of data documents that some patients have to be surgical revised due to weight regain or gastro-esophageal reflux disease. This study elaborates weather Roux-en-Y gastric bypass (RYGB) or Mini/One anastomosis gastric bypass (MGB/OAGB) is a better second step procedure after failed sleeve gastrectomy.
Endoscopic complications such as gastro-esophageal reflux disease, ulcera, gastritis, bile reflux, anastomotic stricture and so on are described after gastric bypass surgery. The incidence of these complications after RYGB versus MGB/OAGB are getting observed.
The frequency of super-super obese who need immediate weight loss surgery is risen continuously. For those patients a prior-to-surgery conditioning therapy is mandatory to gain technical and physical operability. The exclusively well-established preliminary therapy so far was the intragastric balloon, which takes 7 months of treatment time. Due to life-threatening conditions of giant obese patients, who have been admitted to hospital, the investigators were forced to develop a more prompt acting conditioning therapy to bring those individuals in a short run to an improved and "fit-for-surgery" state. In such an impasse the investigators combine Liraglutide with its well-known weight-loss effect with a leucine-based amino acid infusion that is generally used for patients with liver insufficiency, in expectance of an additional weight loss and liver reduction effect.
Today sleeve gastrectomy is the most performed bariatric procedure worldwide. Since 2005 it is gaining popularity as a single procedure. Long term data is scarce. In this retrospective study long term follow-up in relation to weight loss, comorbidities, re-do and revisional surgery is getting analyzed.
Obesity is the indication for bariatric surgery in type I diabetes. Interestingly postsurgery the patients improve remarkable in their need for insulin, not only in the daily total insulin dosage but also in the dosage of IU per kg.
--> Sana for private equity | Sana Products Sana Sana Learn Capabilities Overview AI agents Enterprise search Integrations Security Solutions Industries Financial services Consulting firms Law firms Tech companies Private equity Industrial companies Teams Sales & GTM Marketing Operations Customer support Resources Events Podcast Stories Pricing Mission Careers Log in Mission Careers Log in Book an intro Private equity Sana Book an intro Find your plan Discover why the world’s leading private equity firms are creating expert AI agents on Sana. Driving AI ROI for investors “With Sana, we’re crea
Sana Biotechnology names Brian Piper CFO | SANA 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas Defen … #8220;RSUs”), in each case pursuant to the Company’s 2021 Incentive Award Plan, as amended. The Option has an exercise price equal to the closing price of the Common Stock on the grant date and a term of 10 years from the grant date. The Option will vest with respect to 25% of the shares subject to the Option on the first anniversary of the grant date and 1/48 of the shares subject to the Option monthly thereafter, and the RSUs will vest over four years in equal a … ll vest over four years in equal annual installments on each anniversary of the grant date, in each case, subject to Mr. Piper’s continued service to the Company through each applicable vesting date.   Pursuant to the Offer Letter, upon Mr. Piper’s termination of employment by the Company other than for “cause” (and other than due to his death or disability) or his resignation for “good reason” (as each such term is defined in the Offe … th the team to ensure a strong balance sheet, drive operational excellence, and apply disciplined capital allocation in support of our vision for patient impact and shareholder value.”   About Sana Biotechnology Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We … nued service with the company. What equity awards did Sana Biotechnology (SANA) grant to its new CFO? Sana granted Brian Piper an option to purchase 900,000 shares of common stock and 200,000 restricted stock units under its 2021 Incentive Award Plan. The option vests 25% after one year then monthly over three years, while RSUs vest in four equal
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
EX-3.1 2 d112159dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 SANA BIOTECHNOLOGY, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Sana Biotechnology, Inc. (the “ Corporation ”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the Corporation is Sana Biotechnology, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on July 13, 2018 under the name FD Therapeutics, Inc. The Amended and Restated Certificate of Incorpora … I. Notwithstanding the foregoing, the provisions of this Article VIII shall not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts of the United States have exclusive jurisdiction. If any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever, (a) the validity, … orceable) shall not in any way be affected or impaired thereby and (b) the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. A-5 ARTICLE IX AMENDMENTS Notwithstanding any other provisions of this Amended and Restated Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any
Sana Biotechnology Announces Appointments to its Board of Directors - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved PRESS RELEASE Back Sana Biotechnology Announces Appointments to its Board of Directors January 08, 2021 Share: Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, join Sana Board of Directors SEATTLE — Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D.,
I am thrilled to join Sana Biotechnology, Inc.’s team and be a contributor to its life-changing mission to modify genes and use cells as medicines. I’ve wanted to serve on the board of a company… | Michelle Seitz LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an
Sana Biotechnology adjusts director board class balance | SANA 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks
--> Sana Products s.r.o. | Exhibitor Ambiente 2026 Skip Back Close navigation Home About Ambiente Facts & Figures About Ambiente Dining Living Giving Global Sourcing Ambiente 365 days a year Ambiente Partners & Cooperations – Messe Frankfurt Ambiente worldwide Sustainability Exhibitors & Products Exhibitor search Ambiente 2026 Themes & Events Overview of the programme All Themes & Events Ambiente Projects Ambiente Trends 26+ Design Ethical Style Academies Media library Planning & Preparation For visitors and exhibitors Overview Partnership For Visitors For Exhibitors Re … ups, facts and figures from Ambiente. Events at Ambiente Special presentations, award ceremonies and lectures at Ambiente. Discover now! Conzoom Solutions News, expert knowledge & inspiration - the content hub for retailers. Stay up to date Subscribe to our newsletter Follow us on instagram linkedin facebook youtube If you need more help, let us know Contact Previous Next Imprint Privacy policy GTC © Messe Frankfurt Exhibition GmbH
Board of Directors Archives - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Department: Board of Directors Hans Bishop December 17th, 2019 by admin Hans E. Bishop has served as Chairman and a member of our Board since October 2018. Mr. Bishop has more than 30 years of experience in the biotechnology industry. Mr. Bishop is a founder and has served as President and co-chair of the board of directors of Altos Labs, Inc., a private biotechnology company, since January 2022. Prior to Altos [
SANA Back SANA Gold Exhibiting Sponsor Team Neea Jussila
Press Release Archives - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Category: Press Release Sana Biotechnology Announces Appointments to its Board of Directors January 8th, 2021 by admin Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, join Sana Board of Directors SEATTLE — Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been a … nsion Plan Investment Board, Baillie Gifford, F-Prime Capital, Alaska Permanent Fund, the Public Sector Pension […] Posted in Press Release No Comments Tags: Financing , Sana Biotechnology , Biotech , biotechnology Stacey Ma, Ph.D., Joins Sana Biotechnology as Executive Vice President, Technical Operations March 21st, 2019 by admin SEATTLE — Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines for patients, announced t
2026 SANA Food catalog | Sana VISITORS RESERVED AREA Follow us #SANAFood2027 ITA ENG HOME EXPLORE The Exhibition Focus 2027: Longevity Nutrition SANA Novità EXHIBIT Exhibit at SANA Food 2027 Important notice VISIT 2026 SANA Food catalog Guide to New Products BUYERS PROGRAM Buyers Program PRESS Press release Press Review News Face to face with... Newsletter Photogallery Videogallery CONTACTS Contacts International Network VISITORS RESERVED AREA ITA ENG 2026 SANA Food catalog HOME VISIT 2026 SANA FOOD CATALOG The SANA Food 2026 online catalog will be available soon. In the meantime, view/d
Does Sana Biotechnology Sponsor H1B & Green Card Visas? | Ellis Home Services Pricing About Resources Login Schedule a Call Services From employment-based visas to family petitions, adjustment of status, and everything in between—we handle all immigration matters. The options shown here are just some of our most common services. Get In Touch Visa Options H-1B $3,000 H-1B1 $3,000 TN $2,500 O-1 $12,000 L-1 $10,000 J-1 $2,500 E-1/E-2 $10,000 E-3 $3,000 Green Card Options EB-1A $12,000 EB-2 NIW $12,000 EB-2 PERM $12,000 EB-3 PERM $12,000 Other Naturalization $5,000 Resources Tools Visa Sponsor … mate your H-1B lottery chances News DHS Proposes 75% Increase to US Citizenship Application Fee Supreme Court Ruling on Birthright Citizenship: What It Means for Families H-1B Visa Update: $100,000 Fee Temporarily Reinstated Following Court Stay Judge Strikes Down Trump's $100,000 H-1B Visa Fee — But Can It Return? Is USCIS Really Ending Adjustment of Status? An Immigration Attorney's Analysis of the May 2026 Memo See all news Articles Birthright Citizenship in the
Sana's islet cell transplant therapy shows early promise in type 1 diabetes | News | European Pharmaceutical Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Bioprocessing QA Topics Back to parent navigation item Topics Analytical and bioanalysis Bioprocessing and biomanufacturing Qua
Sana Biotechnology (SANA) Stock Price & Overview Skip to main content Log In Sign Up Home Watchlist Stocks Stock Screener Stock Exchanges Comparison Tool Earnings Calendar By Industry Stock Lists Top Analysts Top Stocks Corporate Actions IPOs Recent IPOs IPO Calendar IPO Statistics IPO News IPO Screener ETFs ETF Screener Comparison Tool New Launches ETF Providers News Trending Articles Technical Chart Fundamental Chart Market Movers Top Gainers Top Losers Most Active Premarket After Hours Market Heatmap Market Newsletter Stock Analysis Pro Tools Collapse Sana Biotechnology, Inc. (SANA) NAS
Sana Biotechnology - Supply Chain & Logistics for Cell & Gene Therapies Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. Returning 2027 About About Event Events in the Series Hanson Wade Products What’s On? Previous Event Guide Previous Speakers Why Partner Why Partner 2026 Partners 2026 Media Partners Take Part Register Interest Contact Us Previous Event Guide Register Interest About About Event Events in the Series Hanson Wade Products What’s On? Previous Event Guide Previous Speakers Why Partner Why
Conformed Copy - C3209 - Sana'a Water Supply and Sanitation Project - Supplemental Letter Skip to Main Navigation Trending Data Non-communicable diseases cause 70% of global deaths Who We Are What We Do Where We Work How We Work Work With Us News & Events About the World Bank Group Organization History Archives Experts & Leaders Leadership Boards of Governors Board of Directors Experts Accountability Annual Report World Bank Group Scorecard World Bank Group Finances Access to Information Policies & Procedures Grievance Redress Service Integrity Vice Presidency Accountability Mech … ices Financing Products & Advisory Services Treasury Asset Management Trust Fund Directory KNOWLEDGE World Bank Group Academy Research & Publications Open Data By Country By Indicator Learning Knowledge Repository Regions Africa East Asia and Pacific Europe & Central Asia Latin America & Caribbean Middle East & North Africa, Afghanistan & Pakistan South Asia Country Groups European Union Middle Income Countries Organization of Eastern Caribbean States
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account May 27, 2026 16:05 ET | Source: Sana Biotechnology, Inc Sana Biotechnology to Present at June 2026 Investor Conferences SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will... May 15, 2026 09:00 ET | Source: Sana Biotechnology, Inc Sana Biotechnology Announces Sal
%PDF-1.7 %���� 1 0 obj >/Metadata 4042 0 R/ViewerPreferences 4043 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���MoA ��+����=�/��M��TA!���SA-�_m�Yv2�(�(��>���;��3���o���+�>�z�ǫ���5��8]���8 E#= 9�1�1 &�1�qX�& k ��ͷq �8����Eas�K/>��Ԅ0�2��/z���n��������ۗ�a�f �y=�+K�%�I�r���� �W�Z 0%`B�� 0gB�����!�D)L���!%�f�5������&�� > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj ] /BitsPerComponent 1 … S/Type/Page>> endobj 557 0 obj > endobj 4042 0 obj >stream Microsoft® Word LTSC application/pdf Janet Lam Microsoft® Word LTSC 2021-12-08T14:17:46-05:00 2021-12-08T14:19:08-05:00 2021-12-08T14:19:08-05:00 uuid:EE523ACF-728E-4BF8-BBE4-30FF10501D2E uuid:710dc861-a24a-4e17-95d7-3ed38e3d1035 endstream endobj 4045 0 obj > endobj 4046 0 obj > endobj 4047 0 obj > endobj 4048 0 obj > endobj 4049 0 obj > endobj 4050 0 obj > endobj 4051 0 obj > endobj 4052 0 obj > endobj 4053 0 obj > e
%PDF-1.7 %���� 1 0 obj >/Metadata 281 0 R/ViewerPreferences 282 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\Yo�F~7�����.�t d�� hƞ�Y���{ �ْ,&�);�_�U}PI�� �H5�UwWW}U]�����&�������~U �����ѠX�v4�_��.�7Y>��"?������O��h��������� ��r�1O��8�r�����|��`��#����d�C#�qO�a�F^�� V�`�~�{7%�л�W���q�W���� ~��;������Z\�� Ұ�u bD0��S�d�@�xz���Y�P�^�>~��O�O���?�ۗ��ad>����;>�O N��b���Db�����j0x�{*J���rz�]�cqz�� �� t���� �R�?ޠ�
SG233 / Sana Biotech SG233 / Sana Biotech - LARVOL DELTA Home Next Prev 1 to 1 Of 1 Go to page 1 March 14, 2023 Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire) - "Sana Biotechnology...announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlan
--> Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Confer … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
Sana Distributors-Sana distributors common.javascriptdisabled Logo Search Products Search Products Search (0) (0) You have no items in your shopping cart. My account My account Register Log in Log in Categories Home page Flyers CLEARANCE (254) Sub Category Electronics (56) Kitchen Supplies (52) Health & Beauty (27) Cleaning Supplies (3) Hardware (20) Confectionary (3) Lighters / Smoking (32) Stationary (15) Gifts / Toys (21) Apparel / Decor / Religous Items (5) Essential (16) ELECTRONICS (440) Sub Category Batteries (137) Button Batteries (44) Hair Clippers & Trimmers, Curling Irons &a … (139) LIGHTERS / SMOKING (236) Sub Category Lighters & Lighter Fluids (73) Rolling Papers (38) Cigarette Accessories (21) Pipes (13) Hookah (8) Grinders, Glass bong, Disposable vape (38) Candles (45) STATIONERY (184) Sub Category Coin Boxes & Money Storage (1) Bristol Boards & Paper (20) Arts & Crafts / Colouring Books (37) Pens, Pencils & Markers (63) Tape & Shipping Supplies (19) Calculators & Math Sets (6) Binders, Clipboards & Organizers ( … (139) LIGHTERS / SMOKING (236) Sub Category Lighters & Lighter Fluids (73) Rolling Papers (38) Cigarette Accessories (21) Pipes (13) Hookah (8) Grinders, Glass bong, Disposable vape (38) Candles (45) STATIONERY (184) Sub Category Coin Boxes & Money Storage (1) Bristol Boards & Paper (20) Arts & Crafts / Colouring Books (37) Pens, Pencils & Markers (63) Tape & Shipping Supplies (19) Calculators & Math Sets (6) Binders, Clipboards & Organizers (
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Sana Biotechnology and Mayo Clinic Announce Strategic --> Accessibility: Skip TopNav Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451 April 13, 2026 16:05 ET | Source: Sana Biotechnology, Inc Sana Biotechnology, Inc Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes Initial efforts will include processes and protocols to improve handling of and clinical care inv … s of follow-up to date. The company expects to file an Investigational New Drug application and initiate a Phase 1 clinical study of SC451 as early as this year. About Sana Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together t … ectations, including with respect to a potential investigational new drug (IND) application and clinical trial; the potential advantages of SC451, including with respect to scalability and the potential to be a single treatment for patients with T1D that leads to long-term glucose control without the need for exogenous insulin or immunosuppression; Sana’s vision and business plans; the potential significance and impact of data from an investigator-sponsored clinical trial eva
Sana - Future of Work Series 2026 Skip To Main Content Global Sponsors Sana Sana is an AI company pioneering the next generation of knowledge tools for the enterprise. Its products are trusted by innovators and market leaders alike—including Merck, Hinge Health, Electrolux, and Svea Solar. In the HR field, Sana is best known for its AI-native learning platform. The enterprise-grade solution helps companies upskill and train their employees more effectively at scale by leveraging artificial intelligence to automate learning management, accelerate content creation, and
#onesana #humantogether #ide #allyship #sponsorship | Sana Biotechnology, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Ag
Sponsor Overview - Transform Conference Transform 2027 Transform FastPass Speakers Pitch the Future Sponsors Register Now Community Sign In Memberships Transform Exec Get Involved 2026 Award Winners Impact Sponsorships Overview Transform FastPass 2026 Sponsors Companies Attending Content Hub Behind the Keynote Overview Articles Videos About Overview Contact Register Now Connect to the global community transforming the future of people + work Transform is where senior practitioners, founders, investors, and innovators come together to move the world of work forward. Request a Prospectus Registe … h more information. Web-to-Lead — Salesforce Request Our Sponsorship Prospectus Submit your details and we’ll contact you shortly. --> Request Our Sponsorship Prospectus Thank you for Submitting your request… you’ll be redirected shortly. --> First Name * Please complete this required field. Last Name * Please complete this required field. Email * Company Name * Job Title * Which category best describes your company’s solution? - Please choose an option - L&D Talent Managemen
--> Sponsors | South Asian Network Of Actuaries top of page Home About Our Story Mission Workstreams Timeline Meet The Team Gallery Get Involved Become A Member Sponsors Donate Volunteer with SANA Micro-Volunteering Resources Job Postings SANA Newsletter Scholarship Events The Infinite Opportunity Career Fair Upcoming Events Past Events Contact Members Get To Know SANA Blog Forum Team More Use tab to navigate through the menu items. Volunteering Opportunities! Log In DONATE Become a SANA Sponsor South Asian Network of Actuaries has its 501(c)(3) status and is collecting intent of sponsorship. … “Corporate Sponsors”. We will reach out to you to obtain information and logo. Submit Intent for Donation Meet The Sponsors! SANA Newsletter Sign Up Are you? * Required Aspiring Actuaries Industry Professional Partners, Sponsors and Allies Sign Up Thanks for subscribing! Home Home ©2022 by SANA. Proudly created with Wix.com bottom of page
Dear SANA... - SANA - South African Nursery Association Facebook Log In SANA - South African Nursery Association's Post SANA - South African Nursery Association September 30, 2025 · Shared with Public Dear SANA Members, Join us for the SANA Sponsorship Day! Discover how your business can gain visibility, add value, and make an impact in the green industry through sponsorship with SANA. Date: Wednesday, 5 November 2025 Time: 10:00 Venue: Heckers Garden Centre Don’t miss this opportunity to explore sponsorship packages, connect with current sponsors, and see how SANA sponsorship can make a
SANA BIOTECHNOLOGY H-1B Visa Sponsorship: 116 LCA Filings | layoffhedge layoff hedge Get Hired H-1B Join Us? Home › H-1B Explorer › SANA BIOTECHNOLOGY SANA BIOTECHNOLOGY H-1B Visa Sponsorship FY2015 to FY2026 · U.S. Department of Labor LCA disclosure data LCA Filings 116 National Rank #6281 of 9,347 Median Wage $115,525 States With Filings 3 SANA BIOTECHNOLOGY ranks #6281 of 9,347 employers tracked on the layoffhedge H-1B Explorer, with 116 LCA filings from FY2015 through FY2026. The median reported wage across its filings is $115,525. Its largest state footprint is Califo … 1B Explorer → Source and method. U.S. Department of Labor, Labor Condition Application (LCA) disclosure files, FY2015 through FY2026. Each certified LCA filing counts once, regardless of how many worker positions it covers. FY2026 includes Q1 only (October to December 2025). Median wage is the median of reported LCA wages for this employer. An LCA is a required first step of the H-1B process and does not by itself mean a visa was issued. Data free to cite with attributio
SANA Sponsorship Bursaries Bursary Applications Events Calendar 2026 Diary SANA Convention SANA Convention 2026 Golf Day SANA Trade Fairs SANA Autumn 2026 Trade Fair GCA Garden Centres Green Business Magazine Life Is A Garden Trade Page Member Resources Trends/Insights Guidelines: Competition Act Bulletin Board Environmental Responsibility Carbon Calculator Chemicals Energy Invasive Alien Plants Recycling Environmental Notices Government Notices Training SANA Workshops Member Surveys Tenders Job Portal Available Positions Job Seekers Awards SANA Honorary Members SANA Awards Young SANA Awards G … of Excellence Supplier Competition Retailer Competition #SANA Heroes Membership Application Forms Benefits Membership application procedure Member Special Deals Partnerships and Affiliations AgriSA FTFA IGCA South African Green Industries Council Working For Water Association Information About Us Exco Structure SANA Constitution Code Of Conduct SANA Forums SANA Sponsors SANA South African Nursery Association Home About SANA SANA Structure Membership Benefits Code Of Conduct S … SANA Structure Membership Benefits Code Of Conduct SANA Constitution Bursaries Bursary Applications Hire Me SANA Sponsorship Association Information SANA Trade Fairs Retailer Competition International Garden Centre Association Partnerships and Affiliations Events Events Calendar 2026 SANA Workshops Green Business Magazine Contact us Coronavirus Resource Centre SANA Sponsorship SANA has developed a strong sponsorship model which helps your association in numerous ways
2025 CEO Chat: Steve Harr, CEO of Sana Biotechnology | Christine Heenan LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement
2025 CEO Chat: Steve Harr, CEO of Sana… | Flagship Pioneering Skip to content Companies Partnerships Initiatives Pioneering Medicines Pioneering Intelligence Preemptive Health & Medicine Flagship Global Engagement Content News Original Content About About Flagship People Our Process Our Values Social Impact Join Us Our Culture Open Roles Flagship Fellowship Open Search Open Menu Human Health 2025 CEO Chat: Steve Harr, CEO of Sana Biotechnology 01.14.2025 Video Share Share on LinkedIn Share on Twitter Steve Harr, CEO of Sana Biotechnology , discusses the year ahead for Sana following the co … le Our Process Our Values Social Impact Join Us Our Culture Open Roles Flagship Fellowship Contact Careers News Privacy Policy Terms of Use
--> SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes top of page Home Quick Takes Around Kendall Science Spotlight BiotechTV U Company News Bright Minds Shows Biotech Direct BioVenture VoiCes Biotech CEO Sisterhood The Studio at Kendall Square Off-Target Effects with Matt Gline Tech + Tours SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes Jan 15 1 min read He describes one patien
Steve Harr, MD - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Our Team Steve Harr, MD CEO, Director Back to Our Team Back Steven D. Harr, M.D. is a co-founder of Sana and has served as our President and Chief Executive Officer since September 2018 and as a member of our Board since October 2018. Prior to Sana, Dr. Harr served as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, Inc. from April 2014 until its acquisition by Celgene Corporation in March 2018.
Steve Harr, MD - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Our Team Steve Harr, MD President and Chief Executive Officer Back to Our Team Back Steve Harr, MD, is President and Chief Executive Officer of Sana Biotechnology. Prior to co-founding Sana, Steve served as Chief Financial Officer and Head of Corporate Development for Juno Therapeutics until its acquisition by Celgene in early 2018. He was a member of the Board of Directors of Loxo Oncology prior to its acquisition by Eli Lil
Sana Biotechnology: SANA Stock Price Quote & News | Robinhood Log In Sign Up Learn Blog Careers Help Log In Sign Up Sana Biotechnology 1D 1W 1M 3M YTD 1Y 5Y ALL Why Robinhood? Robinhood gives you the tools you need to put your money in motion. You can buy or sell SANA and other ETFs, options, and stocks. Sign up About SANA Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. Show more CEO Steven D. Harr CEO Steven … uy or sell SANA stocks, ETFs, and their options commission-free. Other fees may apply. See Robinhood Financial's fee schedule to learn more. Sign Up to Buy Trade SANA Options Watch SANA
SANA Stock Quote Price and Forecast | CNN CNN values your feedback 1. How relevant is this ad to you? 2. Did you encounter any technical issues? Video player was slow to load content Video content never loaded Ad froze or did not finish loading Video content did not start after ad Audio on ad was too loud Other issues Ad never loaded Ad prevented/slowed the page from loading Content moved around while ad loaded Ad was repetitive to ads I've seen previously Other issues Cancel Submit Thank You! Your effort and contribution in providing this feedback is much appreciated. Close Ad Feedback C … at June 2025 Investor Conferences by GlobeNewswire May 20, 2025 10:14am ET SANA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA by Newsfile May 19, 2025 5:50pm ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology by Newsfile May 18, 2025 8:12am ET SANA DEADLINE NOTICE: ROSEN, TOP RANKED GLOB … estors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA by Newsfile May 17, 2025 7:49am ET ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology by Newsfile May 16, 2025 4:00pm ET SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action La … pportunity to Lead Class Action Lawsuit by Newsfile May 16, 2025 2:12pm ET SANA DEADLINE TUESDAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA by Newsfile May 15, 2025 2:07pm ET SANA DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before I … estors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA by Newsfile May 15, 2025 11:13am ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology by Newsfile May 14, 2025 2:02pm ET SANA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSE
Sana is transforming medicine by treating… | Flagship Pioneering Skip to content Companies Partnerships Initiatives Pioneering Medicines Pioneering Intelligence Preemptive Health & Medicine Flagship Global Engagement Content News Original Content About About Flagship People Our Process Our Values Social Impact Join Us Our Culture Open Roles Flagship Fellowship Open Search Open Menu Companies Sana Biotechnology What if… We could deliver any biotherapeutic payload to any cell in the body? It turns out… We can efficiently deliver protein and nucleic acid therapeutics into specific cells by en … payload into the cell cytoplasm. Fusogens are essential to life: The 2013 Nobel Prize was awarded for seminal work uncovering the critical role that fusogens play in intracellular biology, where vesicles programmatically fuse with one another, allowing entire repertoires of biomolecules to specifically and efficiently enter another membrane-enclosed region of the cell. Breakthrough Fusogens function as remarkable mechanical enzymes that can overcome the repulsive forces of br … le Our Process Our Values Social Impact Join Us Our Culture Open Roles Flagship Fellowship Contact Careers News Privacy Policy Terms of Use
Dhavalkumar Patel M.D., Ph.D. - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Dhavalkumar Patel M.D., Ph.D. EVP, Chief Scientific Officer at Sana Biotechnology, Inc. Dhavalkumar Patel M.D., Ph.D. 's Executive Work History Current Board Member , Board Member Equilar on 01/22/2026 Priothera Ltd. Board Member , Board Member Equilar on 04/30/2025 Anokion EVP, Chief Scientific Officer , E … e indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel served as a member of the Board of Directors of Inflazome prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Priothera, Quell Therapeutics, and RE-AIM Therapeutics, and serves as Chair of the Board of Directors for Mimetas BV. Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy … e indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel served as a member of the Board of Directors of Inflazome prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Priothera, Quell Therapeutics, and RE-AIM Therapeutics, and serves as Chair of the Board of Directors for Mimetas BV. Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy
Harbour BioMed appoints Sana Biotechnology CSO Dhavalkumar Patel as scientific advisor Download About Us Support العربية Invest Products Pricing Academy Free Stocks Hot Trading Sahm ID My Account Log Out Sign up / Log in Open Account Open Account Home News Detail Harbour BioMed appoints Sana Biotechnology CSO Dhavalkumar Patel as scientific advisor Reuters 12/06 04:19 العربية Like Facebook Twitter Email Link Share Facebook Twitter Email Link Cancel Sana Biotechnology, Inc. Sana Biotechnology, Inc. SANA 0.00 0.00% HBM Holdings said Harbour BioMed appointed Dhavalkumar Patel as a scientific advi
Sana EVP Patel reports initial equity holdings | SANA Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil … it represents a contingent right to receive one share of Sana common stock. The award vested as to 25% of the restricted stock units on August 26, 2025 and the remaining restricted stock units will vest in three equal installments on each of August 26, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. The award vested as to 25% of the restricted stock unit … represents a contingent right to receive one share of Sana common stock. 5. The award vested as to 25% of the restricted stock units on August 26, 2025 and the remaining restricted stock units will vest in three equal installments on each of August 26, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. 6. The award vested as to 25% of the restricted stock u
Our Team - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Our Team Senior Leadership & Board Senior Leadership Steve Harr, MD President and Chief Executive Officer John Gerecitano, MD, PhD Head of Oncology Research and Development Aaron Grossman Executive Vice President, Chief Legal Officer Gary Meininger, MD Chief Medical Officer Dhavalkumar Patel, MD, PhD Chief Scientific Officer Snehal Patel Chief Technical Officer Brian Piper Executive Vice President, Chief Financial Officer Yuko Sone
Senior Leadership Archives - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Department: Senior Leadership Steve Harr, MD November 27th, 2019 by admin Steve Harr, MD, is President and Chief Executive Officer of Sana Biotechnology. Prior to co-founding Sana, Steve served as Chief Financial Officer and Head of Corporate Development for Juno Therapeutics until its acquisition by Celgene in early 2018. He was a member of the Board of Directors of Loxo Oncology prior to its acquisition by [&hel
Dhavalkumar Patel, MD, PhD - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Our Team Dhavalkumar Patel, MD, PhD Chief Scientific Officer Back to Our Team Back Dhavalkumar Patel, MD, PhD, is Executive Vice President and Chief Scientific Officer of Sana Biotechnology. Prior to joining Sana in 2024, Dhaval served as Executive Vice President and Chief Scientific Officer of UCB, a multinational biopharmaceutical company headquartered in Brussels, Belgium, where he and his teams contributed to … e indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dhaval served as a member of the Board of Directors of Inflazome Ltd. prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Anokion SA, Priothera Ltd., and Quell Therapeutics Limited and serves as Chair of the Board of Directors for Mimetas BV. Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, All
Portfolio - ARCH Venture Partners You are using an outdated browser. Please upgrade your browser to improve your experience. Toggle navigation About Portfolio Initiatives Strategic Partnerships Team News Contact Our Portfolio We build disruptive companies. Meet them. Read what our entrepeneurs are saying about ARCH. Agios Pharmaceuticals --> “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress. ARCH is unique in its ability to see the waves before they start to form. They were the initial glue that brought our scie … htful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scango … htful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scango
JPM2026: Steve Harr Discusses SC451 and Fusogen Platform | Sana Biotechnology, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Exhibitor Details Skip to content Press Escape to close the menu. Expand Portfolio Africa Asia Pacific 180/Jun/2026 Cannes 334/Nov/2026 Palais des Festivals et des Congrès Latin America 123/May/2027 Fundação Bienal de São Paulo North America 271/Sept/2026 Baha Mar Collapse Global Navigation 03 - 06 May 2027 São Paulo, Brazil Take Part Exhibitor Login About Media Partners Sponsors Attend Prepare to attend Venue and travel Exhibit Interested in Exhibiting? Prepare to exhibit Lead manager Key contacts Buyers Prepare to attend Terms & Conditions Key contacts Exhibitor Directory Product Directo
Sana acquired by Workday for $1.1bn, a Stockholm tech success story | Seb Johnson 📊🇪🇺 posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
The Hard Truth About Recognition in the Workplace | Dhavalkumar Patel posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Exhibitor details Skip to content Press Escape to close the menu. All Events Germany 08.04.2027 Messegelände Köln Arabia 08.09.2026 Riyadh Front Collapse Global Navigation 8–11 April 2027 Exhibition Centre Cologne English Deutsch English Register interest Exhibitor enquiry About Partners Visit FIBO Championships FIBO Campus Hallplan Prepare to visit Venue and travel Using your Smart Badge Media and press Stars at the Booth Female Award Book accommodation Exhibit Halls and topics Prepare to exhibit Lead Manager Exhibitor Directory Product directory Show Programme FIBO Congress Longevity in Hosp
Strategic Synthesis Of ASGCT And ASCO 2026 Get more Drug Discovery insight with our FREE newsletter sign me up Log In or Subscribe Topics Bioinformatics Regulatory Target Research Innovation Preclinical Entrepreneurship Partners & Suppliers Research Partners Cellular Models Target Discovery Assay & Screening Imaging & Translational Models Analytical Characterization Watch Now Drug Discovery Online Live Guest Column | June 10, 2026 Strategic Synthesis Of ASGCT And ASCO 2026 By Johnathon Anderson, Ph.D. The spring 2026 conference season made one thing obvious to those of us watching
What are the primary areas of focus for Sana Biotechnology? Products Data Feature Plans Request Demo Sign Up for Free What are the primary areas of focus for Sana Biotechnology? 20 March 2025 Overview of Sana Biotechnology Sana Biotechnology is a pioneering biotechnology company with a bold vision to transform medicine through the use of engineered cells. At its core, the company is focused on designing, creating, and delivering cells as medicines that have the potential to repair or replace damaged tissues, control gene expression, and provide novel therapeutic options across a broad range of
A Dendritic Cell Vaccine Was Safe and Induced Immune Responses in Patients With Multiple Myeloma | AACR | News Releases × Advanced Search Search for: Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off. Patient / Caregivers / Public Researchers / Professionals AACR Foundation AACR's Impact About Cancer Get Involved Innovators in Discovery Patient Advocacy Progress Against Cancer Survivor Journeys Ways to Give AACR Blog AACR Fellows AACR History AACR Newsroom Stories of the AACR Awa … our Grants Program Research Funding Impact AACR Efforts to Protect NIH Funding Apply for Funding Funded Research Funded Research Research Training and Fellowships Career Development Awards Independent Research Grants Ways to Give Travel Grants Publications Publications Scientific Journals Scientific Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Cancer Re … m AACR Stories AACR Stories The Faces and Voices Behind the Science Research We Fund Collaborations Supporters AACR Scientific Journals AACR Meetings AACR Project GENIE AACR Foundation Where Your Money Goes Get Involved Get Involved DIY Fundraising Share Your Story Share Your Story Read Stories from Cancer Survivors Events Advocate Run for Research Corporate Partnerships Collaborations AACR Foundation AACR Foundation AACR Foundation Leadership Where Your Money Goes Believe in … log: Cancer Research Catalyst AACR Annual Meeting News The AACR June L. Biedler Prize for Cancer Journalism AACR Annual Impact Report Leadership and Governance Leadership and Governance Officers Board of Directors AACR Foundation Leadership Fellows of the AACR Academy AACR Committees AACR Foundation AACR Foundation AACR Foundation Leadership Support Cancer Research Where Your Money Goes Believe in Progress Podcast History of the AACR History of the AACR AACR Historical Timeli … our Grants Program Research Funding Impact AACR Efforts to Protect NIH Funding Apply for Funding Funded Research Research Training and Fellowships Career Development Awards Independent Research Grants Ways to Give Travel Grants Publications Scientific Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevent
Sana Biotechnology's SC451 Pancreatic Islet Transplant Study | Jon O'Connell posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … ended to treat serious or life-threatening conditions. Applicant is required to submit preliminary clinical evidence suggesting the potential to address unmet medical needs. This designation provides important opportunities during the drug development process, including increased FDA guidance and eligibility for priority and rolling reviews, as well as accelerated approval pathways. By streamlining these regulatory milestones, the program aims to bring transformative innovati … Track Designation (FTD) in 2025 for the treatment of HCC. The FDA's decision to grant RMAT status highlights the clinical potential and innovativeness of RZ-001, particularly following the meaningful interim signals from the Phase 1b/2a clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. "With the RMAT designation, we plan to accelerate our U.S. development and partnership initiatives by initiating formal discussions w … requires manufacturing that matches the precision of the science. Cellares will apply their Cell Shuttle™ and Cell Q™ platforms to ProT-096 and provide regulatory support toward IND submission. A meaningful step toward the clinic and patients is needed. Read more: https://lnkd.in/edqg6Ea9 #CellTherapy #Hematology #ImmuneReconstitution #Biotech #Biomanufacturing #IND Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed … rs discontinuation under the assumption of drug resistance ❌ logic that doesn’t apply for ablative RT☢️ 💡RT☢️ ablate only what is visible , new lesions reflect biology not yet treated ❌ not failur of local treatment☢️ 🌟💁♂️New lesion in Oligometastatic disease not necessarily treatment failure 🟰they are often the next opportunity for ablation
UR startup acquired by biotech firm - Rochester BeaconRochester Beacon UR startup acquired by biotech firm - Rochester Beacon Skip to content Home Contact GO Go Home Jazz Fest Articles & Opinion Beaconomics Community Culture Development Economy & Business Education Environment Government & Politics Health & Science Entrepreneurship & Innovation Justice & Public Safety Policy Wonk Up for Debate Letters Weekly Email Signup Donate to Support Our Work Community Partnerships Events About Us Who’s behind the Rochester Beacon? Our Mission Weekly Email Signup Editorial I
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Sana Commerce - Dynamics 365 Conference in Las Vegas Venue Register Now Event Info Agenda Agenda at a Glance Convince Your Boss Media Kit Venue & Location PMR Pre-Day FAQ Code of Conduct & Cancellation Policy Sponsors 2026 Sponsors Virtual Swag Bag DynamicsCon 2025 Recap DynamicsCon 2025 Slide Decks 2025 Photo Gallery 2025 Sponsors 2025 Newsroom Partner Marketing Event 2025 2025 Agenda 2025 Media Kit Register Now Meet Your Sponsor Sana Commerce Advocate Sponsor Call Sponsor Email Sponsor Visit Website Address US Offices 108 West 39th Street 9th Floor, Suite 900 New York, NY 10018 Social Media
Sana Biotechnology - F-Prime Capital Skip to content F-Prime Capital People Portfolio Impact Search Home People Portfolio Life Sciences Technology Healthtech + Services Crypto Impact About Jobs Fintech Index Sana Biotechnology NASDAQ: SANA Developing cell and gene therapies for complex diseases. Developing cell and gene therapies for complex diseases. Investment Team Stephen Knight, MD Nihal Sinha, MB BChir Sector Life Sciences Category Therapeutics Location Cambridge, MA Initial Investment 2018 Sana Biotechnology, Inc. (NASDAQ: SANA) is focused on creating and delivering engineered cells as m
Workday and Sana Unveil A Bold New Strategy For AI – JOSH BERSIN -- End of the comment --> Skip to content JOSH BERSIN --> Josh Bersin’s 2026 Imperatives: Unlock the roadmap for enterprise AI, exclusively through Galileo Join us at Irresistible 2026 to unlock exclusive research and strategy sessions. Early Bird pricing ends Feb 28. Search for: Home Membership Bersin Research is Back CHRO Insights Vendor Membership Josh Bersin Institute Global HR Excellence Certification Galileo Suite Galileo 100+ Proven Use Cases for Galileo AI in HR Galileo Learn About Us Topics Enterprise Learning HR T
Company: Sana Biotechnology Logo mobilemenu close CMN Live Home Clinical Trials CMN DB 2.0 CRISPRMED CRISPRMED24 CRISPRMED25 CRISPRMED26 WDC CRISPRMED26 Contest CRISPRMED26 Conference Kit CRISPRMED27 CRISPRMED Website Policies EGMEDC CMN Intelligence Webinars CMN Webinars On-demand - All CMN Webinar - Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines CMN Webinar - Taking the Guesswork Out of Drug Development: CRISPR-Select Validates Drug Targets and Drug Responders Early and Conclusively CMN Webinar - Clinical-Grade gRNA for Genomic Medicines: Making Sense … rapeutics has received U.S. FDA clearance of its Investigational New Drug (IND) application for BEAM-304, an in vivo base-editing therapy for... CARBON Newsletter (19 June 2026) - Your Latest... Carbon Jun. 19, 2026 Some of the best links we picked up around the internet Scaling CRISPR-based gene editing through advanced... Sponsored content Jun. 18, 2026 Addressing manufacturing bottlenecks in the transition to clinical scale. Clinical: Single CRISPR Infusion Curbs Hereditar
Yesterday, Sana was officially acquired by Workday for $1.1B. We built a unicorn, and the largest AI acquisition Europe has ever seen! When I joined Sana at the start of the year as the first… | Elina Mäkelä LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any tim
We are excited to be part of the 1st... - DAISY Foundation Facebook Log In DAISY Foundation's Post DAISY Foundation February 5 · Shared with Public We are excited to be part of the 1st Excellence Congress in Nursing and Healthcare in Berlin! Carolyn Fox will attend as an exhibitor and speaker. We are actively shaping the future of nursing and healthcare and look forward to professional exchange, new impulses, and inspiring encounters. More information about the event can be found here: https://www.sana.de/exzellenzkongress2026 We look forward to exciting conversations on site! #TogetherFo
Michelle Seitz, CFA - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Our Team Michelle Seitz, CFA Director Back to Our Team Back Michelle Seitz, CFA has served as a member of our Board since November 2020. Ms. Seitz founded MeydenVest Partners, a private investment and strategic advisory firm, and has served as its Chief Executive Officer since September 2022. Ms. Seitz served at Russell Investments, a privately held global investment solutions provider, as Chief Executive Officer from Se
Brian Piper - Sana Biotechnology Our Story Our Science For Patients Our Pipeline Our Team Join Us Investors Contact ⓒ 2020-2024 Sana Biotechnology. All rights reserved Our Team Brian Piper Executive Vice President, Chief Financial Officer Back to Our Team Back Brian Piper is Chief Financial Officer of Sana Biotechnology. Prior to joining Sana, Mr. Piper served as Chief Financial Officer of Scorpion Therapeutics until its acquisition by Eli Lilly in 2025, and thereafter was Chief Financial Officer of Antares Therapeutics, following its spin-off from Scorpion. Previously, he was Chief Financial
Sana Biotechnology (SANA) Stock News & Updates | StockTitan --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas … y, Inc. develops engineered cells as medicines for patients, with programs that apply cell engineering, hypoimmune platform technology, and fusogen-based delivery. News about SANA commonly covers its type 1 diabetes cell-replacement work, including UP421 and SC451, and its in vivo CAR T program SG293 for CD19-directed therapy in B-cell cancers and B-cell-mediated autoimmune diseases. Company updates also include preclinical and clinical data presentations, research collaborat
Workday acquires Sana, shifting strategy for learning and work. | Josh Bersin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y … es View Profile Follow More from this author Introducing the 2026 HR Pacesetter Award Winners! Josh Bersin 2w Top Ten Reasons You Should Come to IRRESISTIBLE 2026, June 8-10 in Los Angeles Josh Bersin 3mo People Analytics: The Next Big Thing Josh Bersin 1y Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recruitment & HR Customer Experience Real Esta